Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Adlai Nortye Ltd.NASDAQ: ANL

Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025

Accumulated OCI remains negative

Q4 FY2025 Accumulated OCI was -$4.35M, compared with -$4.54M a year earlier. Over 3 fiscal years it compounded at +21.9% a year.

Context

  • Accumulated OCI amounted to 12.6% of total assets at the end of Q4 FY2025, up 6.3 pp from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +4.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$4.35M— QoQ
Last fiscal yearDec 2025
$17.25M+480.3% YoY
Year agoDec 2024
-$4.54M+4.2% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.2%——
1 year+480.3%——
3-year CAGR+21.9%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
17.25M USD
Year-over-year change
+480.3%

Accumulated OCI vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's Dec 2025 Accumulated OCI of -$4.35M is the lowest of the 7 companies compared; the peer median is -$66.5K.
  • Its year-over-year change of +4.2% is the 3rd highest of 6, against a peer median of +0.0%.
  • Accumulated OCI amounts to 12.6% of total assets for ANL, versus a peer median of 0.4%.
ANL Competitors Peer median
Accumulated OCI for ANL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VSTMVerastem, Inc.Mar 2026$8.62M +29.8%—3.8%
APLMApollomics, Inc.Dec 2025$3.44M +0.0%+0.4%51.2%
CGENCompugen Ltd.Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026-$133K -1050.0%—0.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026-$1.13M +10.2%—0.4%
NUVBNuvation Bio Inc.Jun 2026-$2.61M -698.5%—0.4%
ANLAdlai Nortye Ltd.Dec 2025-$4.35M +4.2%+21.9%12.6%
Peer median (excluding ANL) -$66.5K+0.0%+0.4%0.4%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents64.13M42.76M91.49M60.9M23.79M
Short-term Investments53.81M21.29M7.01M7K0
Net Receivables1.93M346K359K1.17M1.39M
Inventory0(3)000
Other Current Assets03000
Total Current Assets124.54M66.3M101.2M64.06M26.89M
Property, Plant & Equipment (Net)6.59M5.88M3.8M2.71M3.02M
Goodwill00000
Intangible Assets97K89K63K40K19K
Long-term Investments0024.85M4.16M4.25M
Tax Assets00000
Other Non-current Assets455K327K282K304K253K
Total Non-current Assets7.14M6.29M28.99M7.21M7.54M
Total Assets131.69M72.59M130.19M71.27M34.43M
Account Payables2.98M13.1M14.35M10.15M12.64M
Short-term Debt10.46M4.31M30.36M26.33M25.25M
Tax Payables00773K75K0
Deferred Revenue03.88M05M0
Other Current Liabilities737.99K290.11M433K(3.06M)597K
Total Current Liabilities17.5M312.65M49.67M45.36M41.63M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)005M00
Other Non-current Liabilities297.56M0000
Total Non-current Liabilities299.62M1.24M5.47M425K1.13M
Total Liabilities317.11M313.89M55.14M45.79M42.76M
Common Stock4K4K11K11K12K
Retained Earnings(209.43M)(268.22M)(373.09M)(429.32M)(464.85M)
Accumulated OCI(1M)9.53M(4.24M)(4.54M)17.25M
Other Stockholders Equity7.61M13.69M18.02M20.31M0
Minority Interest00000
Total Equity(185.43M)(241.29M)75.05M25.49M(8.32M)
Total Debt13.35M6.54M31.55M27.23M26.38M
Net Debt(50.79M)(36.21M)(59.94M)(33.68M)2.59M

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.